Immunization with antibodies that mimic LPS protects against gram negative bacterial sepsis

Journal of Surgical Research

Volumn 69, Issue 2, 1997, Pages 249-254

  Klaerner, Hans G ^a   Dahlberg, Peter S ^a   Acton, Robert D ^a   Battafarano, Richard J ^a   Uknis, Marc E ^a   Johnston, Jennifer W ^a   Dunn, David L ^a  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LIPOPOLYSACCHARIDE; MONOCLONAL ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL MODEL; CONFERENCE PAPER; CONTROLLED STUDY; ESCHERICHIA COLI; FEMALE; GRAM NEGATIVE INFECTION; HOST RESISTANCE; IMMUNIZATION; IMMUNOMODULATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; SALMONELLA MINNESOTA; SEPSIS;

EID: 0031147734     PISSN: 00224804     EISSN: None     Source Type: Journal    
DOI: 10.1006/jsre.1997.5013     Document Type: Conference Paper

References (49)

1. 1. Burd, R. S., Cody, C. S., and Dunn, D. L. Immunotherapy of gram-negative bacterial sepsis. R. G. Landes Company, Austin, TX, 1992.
2. 2. Suffredini, A. F., Fromm, R. E., Parker, M. M., et al. The cardiovascular response of normal humans to the administration of endotoxin. N. Engl. J. Med. 321: 280, 1989.
3. 3. Morrison, D. C., and Ryan, J. L. Endotoxins and disease mechanisms. Annu. Rev. Med. 38: 417, 1987.
4. 4. Tracey, K. J., and Lowry, S. F. The role of cytokine mediators in septic shock. Adv. Surg. 23: 21, 1990.
5. 5. Mayoral, J. L., and Dunn, D. L. Cross-reactive murine monoclonal antibodies directed against the core/lipid A region of endotoxin inhibit production of tumor necrosis factor. J. Surg. Res. 49: 287, 1990.
6. 6. Cody, C. S., Burd, R. S., Mayoral, J. L., et al. Protective antilipopolysaccharide monoclonal antibodies inhibit tumor necrosis factor production. J. Surg. Res. 52: 314, 1992.
7. 7. Battafarano, R. J., Burd, R. S., Cody, C. S., et al. Anti-lipopolysaccharide monoclonal antibodies inhibit macrophage TNF messenger RNA synthesis in vitro. J. Surg. Res. 54: 342, 1993.
8. 8. Mayoral, J. L., Schweich, C. J., and Dunn, D. L. Decreased tumor necrosis factor production during the initial stages of infection correlates with survival during murine gram-negative sepsis. Arch. Surg. 125: 24, 1990.
9. 9. Battafarano, R. J., Burd, R. S., Kurrelmeyer, K. M., et al. Inhibition of splenic macrophage tumor necrosis factor α secretion in vivo by antilipopolysaccharide monoclonal antibodies. Arch. Surg. 129: 179, 1994.
10. 10. Dunn, D. L., Bogard, Jr., W. C., and Cerra, F. B. Efficacy of type-specific and cross-reactive murine monoclonal antibodies directed against endotoxin during experimental sepsis. Surgery 98: 283, 1985.
11. 11. Teng, N. N., Kaplan, H. S., Hebert, J. M., et al. Protection against gram-negative bacteremia and endotoxemia with human monoclonal IgM antibodies. Proc. Nat. Acad. Sci. U.S.A. 82: 1790, 1985.
12. 12. Dunn, D. L., Bogard Jr., W. C., and Cerra, F. B. Enhanced survival during murine gram-negative bacterial sepsis by use of a murine monoclonal antibody. Arch. Surg. 120: 50, 1985.
13. 13. Dunn, D. L., Priest, B. P., and Condie, R. M. Protective capacity of polyclonal and monoclonal antibodies directed against endotoxin during experimental sepsis. Arch. Surg. 123: 1389, 1988.
14. 14. Ziegler, E. J., Fisher Jr., C. J., Sprung, C. L., et al. and the HA-1A Sepsis Study Group. Treatment of gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin. A randomized, double-blind, placebo-controlled trial. N. Engl. J. Med. 324: 429, 1991.
15. 15. Greenman, R. L., Schein, R. M., Martin, M. A., et al. and the XOMA Sepsis Study Group. A controlled clinical trial of E5 murine monoclonal IgM antibody to endotoxin in the treatment of gram-negative sepsis. JAMA 266: 1097, 1991.
16. 16. Weiss, J., Elsbach, P., Olsson, I., et al. Purification and characterization of a potent bactericidal and membrane active protein from the granules of human polymorphonuclear leukocytes. J. Biol. Chem. 253: 2664, 1978.
17. 17. Elsbach, P., Weiss, J., Franson, R., et al. Separation and purification of a potent bactericidal/permeability-increasing protein and a closely associated phospholipase A2 from rabbit polymorphonuclear leukocytes. J. Biol. Chem. 254: 11000, 1979.
18. 18. Kelly, C. J., Cech, A. C., Argenteanu, M., et al. Role of bactericidal/permeability-increasing protein in the treatment of gram-negative pneumonia. Surgery 114: 140, 1993.
19. 19. Gazzano-Santoro, H., Parent, J. B., Grinna, L., et al. High-affinity binding of the bactericidal/permeability-increasing protein and a recombinant amino-terminal fragment to the lipid A region of lipopolysaccharide. Infect. Immun. 60: 4754, 1992.
20. 2-terminal fragment cause killing of serum-resistant gram-negative bacteria in whole blood and inhibit tumor necrosis factor release induced by the bacteria. J. Clin. Invest. 90: 1122, 1992.
21. 21. Bauer, R. J., White, M. L., Wedel, N., et al. A phase I safety and pharmacokinetic study of a recombinant amino terminal fragment of bactericidal/permeability-increasing protein in healthy male volunteers. Shock 5: 91, 1996.
22. 22. Schumann, R. R., Leong, S. R., Flaggs, G. W., et al. Structure and function of lipopolysaccharide binding protein. Science 249: 1429, 1990.
23. 23. Wright, S. D., Ramos, R. A., Tobias, P. S., et al. CD14, a receptor for complexes of lipopolysaccharide (LPS) and LPS binding protein. Science 249: 1431, 1990.
24. 24. Lei, M. G., and Morrison, D. C. Specific endotoxic lipopolysaccharide-binding proteins on murine splenocytes. I. Detection of lipopolysaccharide-binding sites on splenocytes and splenocyte subpopulations. J. Immunol. 141: 996, 1988.
25. 25. Lei, M. G., and Morrison, D. C. Specific endotoxic lipopolysaccharide-binding proteins on murine splenocytes. II. Membrane localization and binding characteristics. J. Immunol. 141: 1006, 1988.
26. 26. Lei, M. G., Stimpson, S. A., and Morrison, D. C. Specific endotoxic lipopolysaccharide-binding receptors on murine splenocytes. III. Binding specificity and characterization. J. Immunol. 147: 1925, 1991.
27. 27. Wright, S. D., and Jong, M. T. C. Adhesion-promoting receptors on human macrophages recognize E. coli by binding to lipopolysaccharide. J. Exp. Med. 164: 1876, 1986.
28. 28. Hampton, R. Y., Golenbock, D. T., and Raetz, C. R. H. Lipid A binding sites in membranes of macrophage tumor cells. J. Biol. Chem. 263: 14802, 1988.
29. 29. Wright, S. D. Multiple receptors for endotoxin. Curr. Opin. Immunol. 3: 83, 1991.
30. 30. Hampton, R. Y., Golenbock, D. T., Penman, M., et al. Recognition and plasma clearance of endotoxin by scavenger receptors. Nature 352: 342, 1991.
31. 31. Dahlberg, P. S., Battafarano, R. J., Acton, R. D., et al. Active but not passive immunization protects against gram-negative bacterial infection. Surg. Forum. 46: 63, 1995.
32. 32. Kato, T., Takazoe, I., and Okuda, K. Protection of mice against the lethal toxicity of a lipopolysaccharide (LPS) by immunization with anti-idiotype antibody to a monoclonal antibody to lipid A from Eikenella corrodens LPS. Infect. Immun. 58: 416, 1990.
33. 33. Su, S., Ward, M. M., Apicella, M. A., et al. A nontoxic, idiotope vaccine against gram-negative bacterial infections. J. Immunol. 148: 234, 1992.
34. 34. Field, S., Pollack, M., and Morrison, D. C. Development of an anti-idiotype monoclonal antibody mimicking the structure of lipopolysaccharide (LPS) inner-core determinants. Microb. Pathogen. 15: 103, 1993.
35. 35. Field, S., and Morrison, D. C. An antibody which mimics the inner-core region of lipopolysaccharide protects mice against a lethal challenge with endotoxin. Infect. Immun. 62: 3994, 1994.
36. 36. Burd, R. S., Raymond, C. S., Ratz, C. A., et al. A rapid procedure for purifying IgM monoclonal antibodies from murine ascites using a DEAE-disk. Hybridoma 12: 135, 1993.
37. 37. Jerne, N. K. Towards a network theory of the immune system. Ann. Immunol. 125C: 373, 1974.
38. 38. Jerne, N. K., Roland, J., and Cazenave, P. A. Recurrent idiotopes and internal images. EMBO J. 1: 243, 1982.
39. 39. Perosa, F., and Dammacco, F. Human CD4 "internal antigen" mimicry by anti-idiotypic monoclonal antibodies. Int. J. Clin. Lab. Res. 24: 33, 1994.
40. 40. Perosa, F., Scudeletti, M., Imro, M. A., et al. Human CD4-internal antigen anti-idiotypic monoclonal antibody. J. Immunol. 156: 3563, 1996.
41. 41. Miller, R. A., Maloney, D. G., Warnke, R., et al. Treatment of B-cell lymphoma with monoclonal anti-idiotype antibody. N. Engl. J. Med. 306: 516, 1982.
42. 42. Thieleman, K., Maloney, D. G., Meeker, T., et al. Strategies for production of monoclonal anti-idiotype antibodies against human B-cell lymphomas. J. Immunol. 133: 495, 1984.
43. 43. Meeker, T. C., Lowder, J. N., Maloney, D. G., et al. A clinical trial of anti-idiotype therapy for B-cell malignancy. Blood 65: 1349, 1985.
44. 44. Abbas, A. K., Lichtman, A. H., and Pober, J. S. Cellular and Molecular Immunology. W. B. Saunders Company, 1994.
45. 45. Rietschel, E. T., and Brade, H. Bacterial endotoxin. Sci. Am. 267: 54, 1992.
46. 46. Morrison, D. C., and Ryan, J. L. Bacterial endotoxins and host immune function. Adv. Immunol. 28: 293, 1979.
47. 47. Jacobs, D. M., and Morrison, D. C. Stimulation of a T-independent primary anti-hapten response in vitro by TNP-lipopolysaccharide. J. Immunol. 114: 360, 1975.
48. 48. Mosier, D. E., Zaldivas, N. M., Goldings, E., et al. Formation of antibody in the newborn mouse: Study of T-cell independent antibody response. J. Infect. Dis. 136(Suppl.): 14, 1977.
49. 49. Kayhty, H., Karanko, V., Peltola, H., et al. Serum antibodies after immunization with H. influenza type capsular polysaccharide and responses to reimmunization: No evidence of immunologic tolerance or memory. Pediatrics 74: 857, 1984.